



This is a repository copy of *Effect of selenium supplementation on biomarkers of bone turnover*.

White Rose Research Online URL for this paper:
<https://eprints.whiterose.ac.uk/195243/>

Version: Published Version

Proceedings Paper:

Perri, G., Hill, T., Mathers, J.C. et al. (7 more authors) (2021) Effect of selenium supplementation on biomarkers of bone turnover. In: Proceedings of the Nutrition Society. Irish Section Conference, 22-24 Jun 2021, Online. Cambridge University Press (CUP) , e110.

<https://doi.org/10.1017/s0029665121002330>

© The Authors 2021. Reproduced in accordance with the publisher's self-archiving policy.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Effect of selenium supplementation on biomarkers of bone turnover

G. Perri¹, T. Hill¹, J.C. Mathers¹, J. Walsh², F. Gossiel², K. Winther^{3,4,5}, J. Frölich³,
L. Folkestad^{3,6}, S. Cold⁷ and R. Eastell²

¹Human Nutrition Research Centre, Centre for Healthier Lives, Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK,

²Sheffield University, Department of Oncology and Metabolism, Metabolic Bone Centre, Sorby Wing, Northern General Hospital, Sheffield, UK,

³Department of Endocrinology, Odense University Hospital, Odense, Denmark,

⁴Centre for Diabetes, Academic Specialist Centre, Stockholm, Sweden,

⁵Department of Molecular Medicine and Surgery, Karolinska Institute, Solna, Sweden,

⁶Department of Clinical Research, University of Southern Denmark, Odense, Denmark and

⁷Department of Oncology, Odense University Hospital, Odense, Denmark

Selenium is an essential trace element with roles in musculoskeletal health^(1,2). Osteoclast inactivation is associated with selenium supplementation *in vitro* and selenium status is correlated negatively with markers of bone health^(3,4). However, the impact of selenium supplementation on bone turnover markers (BTM) has not been studied. This study investigated the effects of selenium supplementation for up to 5 years in older people on BTM including osteocalcin, procollagen type 1 N-terminal propeptide (P1NP), carboxy-terminal collagen crosslinks and bone alkaline phosphatase.

490 Danish men and women (60–74 y) were randomised to receive 0, 100, 200 or 300 µg of selenium daily as selenium-enriched yeast. Plasma selenium concentration was measured using inductively-coupled-plasma mass spectrometry and BTMs were measured using an autoanalyser at baseline, 6 months and 5 years in non-fasted samples. Data were analysed by ANCOVA with polynomial contrasts to investigate the shape of the dose-response relationships. Covariates included: age, body mass index, baseline plasma selenium concentration, baseline BTM, smoking, alcohol, supplement use and medication.

Plasma selenium concentration increased significantly with increasing selenium supplementation at 6 months (84.1, 155.2, 212.3, 258.3 ng/ml for placebo, 100, 200 and 300 µg selenium, respectively) ($P < 0.001$) and remained elevated at 5 years (88.2, 156.4, 223.8 and 270.9 respectively) ($P < 0.001$). At 6 months, there was a significant linear decrease in P1NP ($P = 0.036$, $\eta^2 = 0.019$) with increasing selenium supplementation but this effect was not apparent at 5 years. There was no significant effect of selenium supplementation on any other BTM.

Selenium supplementation reduced P1NP at 6 months but there were no significant effects on other BTM or after 5 years. Since P1NP is a marker of osteoblast function, the fall in P1NP with increasing selenium supplementation suggests a reduction in new bone formation. The impact of this change in bone turnover on bone health remains to be determined.

References

1. Moreno-Reyes R, et al. (2001) *J Bone Miner Res* **16**, 1556–63.
2. Zhang Z, et al. (2014) *Biophys Acta* **1840**, 3246–3256.
3. Hoeg A, et al. (2012) *J Clin Endocrinol Metab* **97**, 4061–70.
4. Beukhof CM et al. (2016) *PLoS ONE* **11**, e0152748.
5. Kuo T & Chen CH (2017) *Biomark Res* **5**, 18